Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : La Jolla Pharmaceutical
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Details : La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Brand Name : Giapreza
Molecule Type : Large molecule
Upfront Cash : $22.5 million
January 12, 2021
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : La Jolla Pharmaceutical
Deal Size : $132.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
